Cargando…
Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)
Ankaferd hemostat (Ankaferd blood stopper [ABS], Istanbul, Turkey) is a hemostatic agent affecting red blood cell-fibrinogen interactions. ABS has been traditionally used in Anatolia as a hemostatic agent for centuries. ABS contains a standardized combination of the plants namely Glycyrrhiza glabra,...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026817/ https://www.ncbi.nlm.nih.gov/pubmed/32110403 http://dx.doi.org/10.1177/2050312120907811 |
_version_ | 1783498749251682304 |
---|---|
author | Ciftciler, Rafiye Ciftciler, Ali Erdinc Malkan, Umit Yavuz Haznedaroglu, Ibrahim C |
author_facet | Ciftciler, Rafiye Ciftciler, Ali Erdinc Malkan, Umit Yavuz Haznedaroglu, Ibrahim C |
author_sort | Ciftciler, Rafiye |
collection | PubMed |
description | Ankaferd hemostat (Ankaferd blood stopper [ABS], Istanbul, Turkey) is a hemostatic agent affecting red blood cell-fibrinogen interactions. ABS has been traditionally used in Anatolia as a hemostatic agent for centuries. ABS contains a standardized combination of the plants namely Glycyrrhiza glabra, Thymus vulgaris, Alpinia officinarum, Vitis vinifera, and Urtica dioica. The hemostatic effect of ABS depends upon the quick promotion of a protein network, particularly fibrinogen gamma, in relation to the erythrocyte aggregation. The aim of this review is to indicate pharmacobiological basis and clinical backgrounds of ABS. Current perspective for using ABS is to provide hemostasis and accelerating wound healing particularly in cases which are difficult to manage. Future controlled trials are needed to elucidate the actions of ABS with in hemostasis, antithrombotic, anti-inflammatory, anti-infective, antifungal, and anti-oxidative effects. |
format | Online Article Text |
id | pubmed-7026817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-70268172020-02-27 Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper) Ciftciler, Rafiye Ciftciler, Ali Erdinc Malkan, Umit Yavuz Haznedaroglu, Ibrahim C SAGE Open Med Review Paper Ankaferd hemostat (Ankaferd blood stopper [ABS], Istanbul, Turkey) is a hemostatic agent affecting red blood cell-fibrinogen interactions. ABS has been traditionally used in Anatolia as a hemostatic agent for centuries. ABS contains a standardized combination of the plants namely Glycyrrhiza glabra, Thymus vulgaris, Alpinia officinarum, Vitis vinifera, and Urtica dioica. The hemostatic effect of ABS depends upon the quick promotion of a protein network, particularly fibrinogen gamma, in relation to the erythrocyte aggregation. The aim of this review is to indicate pharmacobiological basis and clinical backgrounds of ABS. Current perspective for using ABS is to provide hemostasis and accelerating wound healing particularly in cases which are difficult to manage. Future controlled trials are needed to elucidate the actions of ABS with in hemostasis, antithrombotic, anti-inflammatory, anti-infective, antifungal, and anti-oxidative effects. SAGE Publications 2020-02-16 /pmc/articles/PMC7026817/ /pubmed/32110403 http://dx.doi.org/10.1177/2050312120907811 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Paper Ciftciler, Rafiye Ciftciler, Ali Erdinc Malkan, Umit Yavuz Haznedaroglu, Ibrahim C Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper) |
title | Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper) |
title_full | Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper) |
title_fullStr | Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper) |
title_full_unstemmed | Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper) |
title_short | Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper) |
title_sort | pharmacobiological management of hemostasis within clinical backgrounds via ankaferd hemostat (ankaferd blood stopper) |
topic | Review Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026817/ https://www.ncbi.nlm.nih.gov/pubmed/32110403 http://dx.doi.org/10.1177/2050312120907811 |
work_keys_str_mv | AT ciftcilerrafiye pharmacobiologicalmanagementofhemostasiswithinclinicalbackgroundsviaankaferdhemostatankaferdbloodstopper AT ciftcileralierdinc pharmacobiologicalmanagementofhemostasiswithinclinicalbackgroundsviaankaferdhemostatankaferdbloodstopper AT malkanumityavuz pharmacobiologicalmanagementofhemostasiswithinclinicalbackgroundsviaankaferdhemostatankaferdbloodstopper AT haznedarogluibrahimc pharmacobiologicalmanagementofhemostasiswithinclinicalbackgroundsviaankaferdhemostatankaferdbloodstopper |